- XpresSpa Group Inc (NASDAQ:XSPA) has extended its initial $2 million airport-based biosurveillance program with the Centers for Disease Control and Prevention (CDC) through its subsidiary XpresCheck. The extension brings the total contract to $5.6 million.
- The COVID-19 biosurveillance program, first launched in September 2021, provided testing for travelers arriving from India at three key U.S. airports, including John F. Kennedy International Airport, Newark-Liberty International Airport, and San Francisco International Airport.
- With the recent expansion, the program now tests passengers entering the U.S. from seven African countries, including passengers making connections through the U.K., France, Germany, and Brazil.
- The expansion includes the addition of Hartsfield-Jackson Atlanta International Airport, bringing the number of testing sites to four.
- Price Action: XSPA shares traded higher by 4.10% at $1.40 on the last check Monday.
Get all your news in one place.
100’s of premium titles.
One app.
Start reading
One app.
Get all your news in one place.
100’s of premium titles. One news app.
XpresSpa Extends Partnership With CDC For Biosurveillance At US Airports
CDC
United States
Brazil
Centers for Disease Control and Prevention
France
Germany
India
San Francisco International Airport
United Kingdom
Sign up to read this article
Read news from 100’s of titles, curated specifically for you.
Already a member?
Sign in here
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member?
Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member?
Sign in here
Our Picks